Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.

Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD.

JCI Insight. 2018 Aug 23;3(16). pii: 99791. doi: 10.1172/jci.insight.99791. [Epub ahead of print]

2.

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.

Lopez G, Braggio D, Zewdu A, Casadei L, Batte K, Bid HK, Koller D, Yu P, Iwenofu OH, Strohecker A, Choy E, Lev D, Pollock R.

PLoS One. 2017 Nov 29;12(11):e0188859. doi: 10.1371/journal.pone.0188859. eCollection 2017.

3.

Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.

Xiao H, Bid HK, Chen X, Wu X, Wei J, Bian Y, Zhao C, Li H, Li C, Lin J.

PLoS One. 2017 Jul 3;12(7):e0180297. doi: 10.1371/journal.pone.0180297. eCollection 2017.

4.

Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Nerve Sheath Tumor Growth via Induction of Apoptosis.

Zewdu A, Lopez G, Braggio D, Kenny C, Constantino D, Bid HK, Batte K, Iwenofu OH, Oberlies NH, Pearce CJ, Strohecker AM, Lev D, Pollock RE.

Clin Exp Pharmacol. 2016 Nov;6(6). pii: 221. doi: 10.4172/2161-1459.1000221. Epub 2016 Oct 24.

5.

BET bromodomain inhibitor (JQ1) and tumor angiogenesis.

Bid HK, Kerk S.

Oncoscience. 2016 Nov 23;3(11-12):316-317. doi: 10.18632/oncoscience.326. eCollection 2016. No abstract available.

6.

Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.

Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K.

Oncogene. 2017 Jan 12;36(2):168-181. doi: 10.1038/onc.2016.197. Epub 2016 Jun 13.

7.

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ.

Mol Cancer Ther. 2016 May;15(5):1018-28. doi: 10.1158/1535-7163.MCT-15-0567. Epub 2016 Feb 23.

8.

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE.

Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16.

9.

HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.

Lopez G, Song Y, Lam R, Ruder D, Creighton CJ, Bid HK, Bill KL, Bolshakov S, Zhang X, Lev D, Pollock RE.

Mol Cancer Res. 2016 Jan;14(1):35-43. doi: 10.1158/1541-7786.MCR-15-0295. Epub 2015 Sep 22.

10.

HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).

Lopez G, Bill KL, Bid HK, Braggio D, Constantino D, Prudner B, Zewdu A, Batte K, Lev D, Pollock RE.

PLoS One. 2015 Jul 22;10(7):e0133302. doi: 10.1371/journal.pone.0133302. eCollection 2015.

11.

Re: bacillus Calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Bid HK.

Eur Urol. 2015 Feb;67(2):351. doi: 10.1016/j.eururo.2014.11.022. No abstract available.

PMID:
25760254
12.

Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor.

McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, Varadharaj S, Zhang J, Hideg K, Houghton P, Kuppusamy P, Cohn DE, Selvendiran K.

Oncoscience. 2014 Mar 31;1(3):216-28. eCollection 2014.

13.

Detection and biological activities of carboxyethylpyrrole ethanolamine phospholipids (CEP-EPs).

Wang H, Guo J, West XZ, Bid HK, Lu L, Hong L, Jang GF, Zhang L, Crabb JW; Clinical Genomic and Proteomic AMD Study Group, Linetsky M, Salomon RG.

Chem Res Toxicol. 2014 Dec 15;27(12):2015-22. doi: 10.1021/tx500216a. Epub 2014 Nov 19.

14.

A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J.

J Biol Chem. 2015 Feb 6;290(6):3418-29. doi: 10.1074/jbc.M114.616748. Epub 2014 Oct 13.

15.

Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.

Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, Raffel C, Studebaker AW.

BMC Cancer. 2014 Mar 19;14:206. doi: 10.1186/1471-2407-14-206.

16.

HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.

Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Res. 2014 Apr 15;74(8):2316-27. doi: 10.1158/0008-5472.CAN-13-2433. Epub 2014 Mar 3.

17.

Link between p53 isoforms and angiogenesis: Current prospects.

Bid HK.

South Asian J Cancer. 2013 Jul;2(3):108. doi: 10.4103/2278-330X.114097. No abstract available.

18.

p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.

Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam H.

J Biol Chem. 2014 Feb 14;289(7):4083-94. doi: 10.1074/jbc.M113.530303. Epub 2013 Dec 23.

19.

ΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis.

Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam H.

Cancer Res. 2014 Jan 1;74(1):320-9. doi: 10.1158/0008-5472.CAN-13-0894. Epub 2013 Oct 23.

20.

Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.

Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ.

Clin Cancer Res. 2013 Dec 15;19(24):6716-29. doi: 10.1158/1078-0432.CCR-13-0842. Epub 2013 Oct 16.

21.

Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.

Hsu SH, Wang B, Kutay H, Bid H, Shreve J, Zhang X, Costinean S, Bratasz A, Houghton P, Ghoshal K.

Am J Pathol. 2013 Dec;183(6):1719-1730. doi: 10.1016/j.ajpath.2013.08.004. Epub 2013 Oct 8.

22.

RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.

Bid HK, Roberts RD, Manchanda PK, Houghton PJ.

Mol Cancer Ther. 2013 Oct;12(10):1925-34. doi: 10.1158/1535-7163.MCT-13-0164. Epub 2013 Sep 26. Review.

23.

Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.

Wang B, Hsu SH, Wang X, Kutay H, Bid HK, Yu J, Ganju RK, Jacob ST, Yuneva M, Ghoshal K.

Hepatology. 2014 Feb;59(2):555-66. doi: 10.1002/hep.26712. Epub 2013 Dec 20.

24.

Vitamin D receptor and type 2 diabetes mellitus: Growing therapeutic opportunities.

Manchanda PK, Bid HK.

Indian J Hum Genet. 2012 Sep;18(3):274-5. doi: 10.4103/0971-6866.107975. No abstract available.

25.

Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ.

Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.

26.

Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia.

Manchanda PK, Kibler AJ, Zhang M, Ravi J, Bid HK.

Indian J Urol. 2012 Oct;28(4):377-81. doi: 10.4103/0970-1591.105745.

27.

Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.

Basappa, Sugahara K, Thimmaiah KN, Bid HK, Houghton PJ, Rangappa KS.

PLoS One. 2012;7(8):e39444. doi: 10.1371/journal.pone.0039444. Epub 2012 Aug 15. Erratum in: PLoS One. 2012;7(10):doi/10.1371/annotation/a685ce21-d7a1-4a5b-8fe8-734a071d53cd.

28.

In vitro anti-breast cancer activity of ethanolic extract of Wrightia tomentosa: role of pro-apoptotic effects of oleanolic acid and urosolic acid.

Chakravarti B, Maurya R, Siddiqui JA, Bid HK, Rajendran SM, Yadav PP, Konwar R.

J Ethnopharmacol. 2012 Jun 26;142(1):72-9.

PMID:
22855944
29.

Polymorphic variations in IL-1β, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women.

Pooja S, Chaudhary P, Nayak LV, Rajender S, Saini KS, Deol D, Kumar S, Bid HK, Konwar R.

Cytokine. 2012 Oct;60(1):122-8. doi: 10.1016/j.cyto.2012.06.241. Epub 2012 Jul 18.

PMID:
22818022
30.

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.

Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ.

PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.

31.

Words of wisdom. Re: Markers predicting response to Bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review.

Bid HK.

Eur Urol. 2012 Apr;61(4):846-7. doi: 10.1016/j.eururo.2012.01.032. No abstract available.

PMID:
22373880
32.

An interleukin-10 gene promoter polymorphism (-592A/C) associated with type 2 diabetes: a North Indian study.

Saxena M, Agrawal CC, Bid HK, Banerjee M.

Biochem Genet. 2012 Aug;50(7-8):549-59. doi: 10.1007/s10528-012-9499-z.

PMID:
22298356
33.

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ.

Mol Cancer Ther. 2012 Mar;11(3):649-59. doi: 10.1158/1535-7163.MCT-11-0575. Epub 2011 Dec 21.

34.

BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Ahirwar DK, Manchanda PK, Mittal RD, Bid HK.

J Cancer Res Clin Oncol. 2011 Dec;137(12):1729-38. doi: 10.1007/s00432-011-1056-3. Epub 2011 Sep 20. Review.

PMID:
21932129
35.

Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents.

Kumar A, Tripathi VD, Kumar P, Gupta LP, Akanksha, Trivedi R, Bid H, Nayak VL, Siddiqui JA, Chakravarti B, Saxena R, Dwivedi A, Siddiquee MI, Siddiqui U, Konwar R, Chattopadhyay N.

Bioorg Med Chem. 2011 Sep 15;19(18):5409-19. doi: 10.1016/j.bmc.2011.07.056. Epub 2011 Aug 2.

PMID:
21871812
36.

Preliminary studies on CD36 gene in type 2 diabetic patients from north India.

Gautam S, Agrawal CG, Bid HK, Banerjee M.

Indian J Med Res. 2011 Jul;134:107-12.

37.

E-nephrology.

Manchanda PK, Bid HK.

Indian J Nephrol. 2011 Jan;21(1):1-9. doi: 10.4103/0971-4065.78295.

38.

Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?

Bid HK, Manchanda PK, Konwar R, Hanif K, Nayak VL, Singh V.

Indian J Urol. 2010 Oct;26(4):497-501. doi: 10.4103/0970-1591.74438.

39.

Chondroitin sulphate decorated nanoparticulate carriers of 5-fluorouracil: development and in vitro characterization.

Yadav AK, Agarwal A, Jain S, Mishra AK, Bid H, Rai G, Agrawal H, Agrawal GP.

J Biomed Nanotechnol. 2010 Aug;6(4):340-50.

PMID:
21323107
40.

Targeting angiogenesis in childhood sarcomas.

Bid HK, Houghton PJ.

Sarcoma. 2011;2011:601514. doi: 10.1155/2011/601514. Epub 2010 Dec 9.

41.

Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population.

Konwar R, Manchanda PK, Chaudhary P, Nayak VL, Singh V, Bid HK.

Asian Pac J Cancer Prev. 2010;11(4):1067-72.

43.

Neo-tanshinlactone inspired synthesis, in vitro evaluation of novel substituted benzocoumarin derivatives as potent anti-breast cancer agents.

Sashidhara KV, Rosaiah JN, Kumar M, Gara RK, Nayak LV, Srivastava K, Bid HK, Konwar R.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):7127-31. doi: 10.1016/j.bmcl.2010.09.040. Epub 2010 Sep 21.

PMID:
20951035
44.

Role of ethnic variations in TNF-α and TNF-β polymorphisms and risk of breast cancer in India.

Pooja S, Francis A, Bid HK, Kumar S, Rajender S, Ramalingam K, Thangaraj K, Konwar R.

Breast Cancer Res Treat. 2011 Apr;126(3):739-47. doi: 10.1007/s10549-010-1175-6. Epub 2010 Sep 28.

PMID:
20878356
45.

Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.

Konwar R, Manchanda PK, Chaudhary P, Nayak VL, Singh V, Bid HK.

Asian Pac J Cancer Prev. 2010;11(2):365-70.

46.

Association of glutathione S-transferase (GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes mellitus in north Indian population.

Bid HK, Konwar R, Saxena M, Chaudhari P, Agrawal CG, Banerjee M.

J Postgrad Med. 2010 Jul-Sep;56(3):176-81. doi: 10.4103/0022-3859.68633.

47.

Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells.

Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK.

Int J Pharm. 2010 Jun 30;393(1-2):185-96. doi: 10.1016/j.ijpharm.2010.04.002. Epub 2010 Apr 9.

PMID:
20382210
48.

Polymorphisms in the vitamin D receptor and the androgen receptor gene associated with the risk of urolithiasis.

Mittal RD, Mishra DK, Srivastava P, Manchanda P, Bid HK, Kapoor R.

Indian J Clin Biochem. 2010 Apr;25(2):119-26. doi: 10.1007/s12291-010-0023-0. Epub 2010 May 27.

49.

Anti-tumor activity of a new series of benzoxazepine derivatives in breast cancer.

Samanta K, Chakravarti B, Mishra JK, Dwivedi SK, Nayak LV, Choudhry P, Bid HK, Konwar R, Chattopadhyay N, Panda G.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):283-7. doi: 10.1016/j.bmcl.2009.10.115. Epub 2009 Oct 30.

PMID:
19932024
50.

Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.

Hanif K, Bid HK, Konwar R.

Hypertens Res. 2010 Jan;33(1):11-21. doi: 10.1038/hr.2009.184. Epub 2009 Nov 13. Review.

PMID:
19911001

Supplemental Content

Support Center